SCHEMBL6799689

SCHEMBL6799689

CN1C2CCC1CC(NC(=O)CN)C2

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 1/20 0.45
HTR4 Q13639 3/20 0.42
TMEM97 Q5BJF2 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
HTR3A P46098 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878767 0.81 MEN1 (0.38) L3MBTL1MEN1KMT2AALDH1A1MAPK1
SCHEMBL3875022 0.81 MEN1 (0.38) L3MBTL1MEN1KMT2AALDH1A1MAPK1
SCHEMBL3875019 0.81 MEN1 (0.38) L3MBTL1MEN1KMT2AALDH1A1MAPK1
SCHEMBL9366512 0.79 MEN1 (0.51) L3MBTL1MEN1KMT2AHTR4ALDH1A1
SCHEMBL6794293 0.79 MEN1 (0.51) L3MBTL1MEN1KMT2AHTR4ALDH1A1
SCHEMBL13525422 0.78 L3MBTL1 (0.49) L3MBTL1MEN1KMT2AMAPTHTR4
SCHEMBL16853217 0.78 SMN1; SMN2 (0.38) MEN1KMT2AALDH1A1LMNA
SCHEMBL9730018 0.77 MEN1 (0.53) L3MBTL1MEN1KMT2AHTR4HTR3A
SCHEMBL9730026 0.77 MEN1 (0.53) L3MBTL1MEN1KMT2AHTR4HTR3A
SCHEMBL2612622 0.77 ALDH1A1 (0.57) L3MBTL1MEN1KMT2AHTR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6734306-B2 USEFUL IN THE TREATMENT OF INFLAMMATION, ASTHMA, ALLERGIC RHINITIS, PAIN OR THE LIKE PFIZER, INC. 2004-05-11 US disclosed
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists PFIZER INC. 2002-09-12 US disclosed
EP-1213289-A1 N-benzenesulfonyl L-proline compounds as bradykinin antagonists PFIZER INC. (US) 2002-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128271-A1 N-benzenesulfonyl l-proline compounds as bradykinin antagonists BDKRB1, HRH2, BDKRB2 L3MBTL1 4055/4885MEN1 3988/4885KMT2A 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.